From NBC News online…
Lesbian, gay, bisexual and questioning (LGBQ) teens are at least twice as likely as their heterosexual peers to use illegal drugs like cocaine, ecstasy, heroin and methamphetamines, a U.S. study suggests. Previous research suggests that stressors related to being closeted or coming out and being rejected by family or friends could contribute to an increased risk of substance use among sexual minority teens, senior study author John Ayers of San Diego State University in California said.
For the new study, researchers looked at data from roughly 14,703 high school students who had been surveyed about their lifetime and prior-month use of 15 different substances, including illegal drugs as well as tobacco, alcohol and prescription drugs that weren’t given to them by a physician.
LGBQ youth were more than three times more likely to try heroin or methamphetamines at least once, and more than twice as likely to try ecstasy or cocaine, the study also found.
Stressors faced by LGBQ teens, such as stigma and isolation, “may make drugs foolishly appear attractive as a coping mechanism,” Ayers said by email. “Even experimentation with these harder drugs can derail a teen’s future,” he said.
The vast majority of teens didn’t use illegal drugs, regardless of sexual orientation, researchers report in the American Journal of Public Health.
Read the full article on NBC News.
Eugene McCray MD
Advances in HIV prevention and program implementation were among the topics in the spotlight at the 22nd International AIDS Conference (AIDS 2018) this week. Eugene McCray, MD, Director of CDC’s Division of HIV/AIDS Prevention (DHAP)
reflects on some of the conference highlights. The division he oversees works to prevent HIV infections and reduce the incidence of HIV-related illness and death across the United States. Read more about their work.
During a live interview on Facebook, Dr. McCray discussed research being presented by CDC researchers at the conference, other HIV prevention research findings shared here at the conference, and shares his personal reflection on what how it feels like to be at this conference at this stage of the epidemic.
Watch the video.
Since PrEP is one of the newer HIV prevention tools, understanding more about who is using it is important to better tailoring HIV prevention efforts at the national, state, and community levels. PrEP, or pre-exposure prophylaxis, is when people at high risk for HIV take HIV medicine daily to lower their chances of getting infected with HIV. AIDSVu has released the first-ever publicly available data and interactive maps of PrEP use by state from 2012 through 2016, stratified by sex and age.
The new maps from AIDSVu show more than 77,000 people were prescribed PrEP in 2016, with an average 73 percent increase year over year in persons using PrEP across the U.S. from 2012 – when the drug TDF/FTC was approved by the FDA for use as PrEP – to 2016. However, approximately 1.1 million people in the U.S. are at substantial risk for HIV exposure and could benefit from PrEP, according to analysis presented by the Centers for Disease Control and Prevention (CDC) at CROI 2018 earlier this year.
The data presented on AIDSVu reveal that the growth and distribution of PrEP use has been inconsistent across different sexes, age groups, and geographic regions. For example, the Southern U.S. accounted for more than half (52 percent) of all new HIV diagnoses in 2016 but represented only 30 percent of all PrEP users in 2016. That same year, women comprised 19 percent of all new HIV diagnoses but made up only seven percent of all PrEP users.
Read the full article.
As a company that serves the LGBTQ community, we understand the sensitivities around HIV status disclosure. Our goal is and always has been to support the health and safety of our users worldwide.
Recently, Grindr’s industry standard use of third party partners including Apptimize and Localytics, two highly-regarded software vendors, to test and validate the way we roll out our platform has drawn concern over the way we share user data.
In an effort to clear any misinformation we feel it necessary to state:
- Grindr has never, nor will we ever sell personally identifiable user information – especially information regarding HIV status or last test date – to third parties or advertisers.
- As an industry standard practice, Grindr does work with highly-regarded vendors to test and optimize how we roll out our platform. These vendors are under strict contractual terms that provide for the highest level of confidentiality, data security, and user privacy.
- When working with these platforms we restrict information shared except as necessary or appropriate. Sometimes this data may include location data or data from HIV status fields as these are features within Grindr, however, this information is always transmitted securely with encryption, and there are data retention policies in place to further protect our users’ privacy from disclosure.
As an industry leader and champion for the LGBTQ community, Grindr, recognizes that a person’s HIV status can be highly stigmatized but after consulting several international health organizations and our Grindr For Equality team, Grindr determined with community feedback it would be beneficial for the health and well-being of our community to give users the option to publish, at their discretion, the user’s HIV Status and their Last Tested Date. It is up to each user to determine what, if anything, to share about themselves in their profile.
The inclusion of HIV status information within our platform is always regarded carefully with our users’ privacy in mind, but like any other mobile app company, we too must operate with industry standard practices to help make sure Grindr continues to improve for our community. We assure everyone that we are always examining our processes around privacy, security and data sharing with third parties, and always looking for additional measures that go above and beyond industry best practices to help maintain our users’ right to privacy.
– Scott Chen, CTO of Grindr
During that time, the rate dropped 15 percent nationally and rose 25 percent among Latino men who have sex with men.
From Poz Magazine online…
While the national annual HIV infection rate dropped by an estimated 15 percent between 2008 and 2015, a few key subgroups saw a rise in yearly new HIV infections, also known as HIV incidence. During this period, HIV incidence among 25- to 34-year-old men who have sex with men (MSM) increased by an estimated 45 percent while the rate increased 25 percent among Latino MSM.
These figures come from the Centers for Disease Control and Prevention’s (CDC) new, in-depth analysis of epidemic trends in the United States. Published in the Annals of Internal Medicine, the report is a more precise and granular version of reports on epidemic trends that CDC officials presented at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle a year ago.
At that time, the agency estimated that HIV incidence declined 18 percent between 2008 and 2014. This new estimate, therefore, represents a disappointing reduction in that hopeful figure.
Prior to 2008, HIV incidence was essentially stable in the United States for the two decades since the beginning of the modern era of combination antiretroviral (ARV) treatment.
Read the full article.
From the New York Times…
State financial regulators in New York said Wednesday that they would investigate reports that gay men have been denied insurance policies covering life, disability or long-term care because they were taking medication to protect themselves against H.I.V.
Such denials would amount to illegal discrimination based on sexual orientation, and the companies doing so could be penalized, said Maria T. Vullo, the state’s superintendent of financial services.
The investigation was triggered by an article published Tuesday by The New York Times, she said.
The Times reported that various insurers around the country had denied policies to gay men after learning they took Truvada, a cocktail of two anti-AIDS drugs, to avoid catching H.I.V. through sex. To get insurance, some men even stopped taking the protective drugs.
The practice — known as “pre-exposure prophylaxis,” or PrEP — is recommended by the Centers for Disease Control and Prevention. Studies have shown that people who take the drug every day have nearly a zero chance of becoming infected, even if they are in a long relationship with an H.I.V.-infected person or have sex with many strangers without condoms.
Read the full article.